Regeneron Pharmaceuticals logo

Sr Research Specialist-PPK/PD

Regeneron Pharmaceuticals

Tarrytown, NY; Atlanta, GA; New York, NY; Buffalo, NY; Alexandria, VA; Newark, NJ; Jersey City, NJ; Elizabeth, NJ; Minneapolis, MN; Garden City, NY; New Haven, CT; Hartford, CT; Bridgeport, CT; Albany, NY; Detroit, MI; Ann Arbor, MI; Anaheim, CA; Colorado Springs, CO; Cambridge, MA; Baltimore, MD; Pittsburgh, PA; Philadelphia, PA; Milwaukee, WI; Green Bay, WI; Cincinnati, OH; Boston, MA; Chicago, IL; Brooklyn, NY; Greensboro, NCHybridPosted 2 days ago$93,900.00 - $153,300.00
Full TimeSenior LevelResearch & ScientistBiotechnology
Original posting ↗

Summary

This individual will serve as an independent contributor in the Translational Pharmacokinetics and Pharmacodynamics (TPK/PD) Group.

Job description

  • Perform non-compartmental and compartmental PK/PD analyses in support of nonclinical and (potentially) clinical studies using Phoenix WinNonlin and other analysis software
  • Prepare and quality-control standardized datasets from CRO and internal bioanalytical data for regulatory submission
  • Contribute to PK/TK protocol design/input
  • Support CRO studies
  • Produce Pharmacometrics deliverables and regulatory tables/figures/listings
  • Follow all SOPs to ensure GxP/GLP compliance

Requirements

  • Expertise in PK/PD analysis
  • Experience with Phoenix WinNonlin or similar analysis software
  • Ability to prepare regulatory deliverables
  • Experience working within a GxP/GLP regulated environment

Benefits

  • Annual bonuses
  • Incentive plans
  • Equity awards
  • Pension or retirement benefits
  • 401(k) company match
  • Health and wellness programs
  • Fitness centers
  • Medical, Dental & Vision
  • Life and disability insurance
  • Paid time off
  • Family support benefits

Company overview

Regeneron Pharmaceuticals is a leading American biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company specializes in inventing, developing, and commercializing life-transforming medicines for people with serious diseases. Regeneron is renowned for its innovative antibody technologies and has developed several groundbreaking therapies, including EYLEA® for retinal diseases, DUPIXENT® for inflammatory conditions, and the COVID-19 antibody cocktail REGEN-COV®. The company operates with a strong focus on research and development across multiple therapeutic areas including ophthalmology, oncology, cardiovascular diseases, and rare genetic disorders. Regeneron's proprietary VelocImmune® technology platform enables the rapid generation of fully human monoclonal antibodies. With over 15,000 employees globally and annual revenues exceeding $14 billion, Regeneron has established itself as a major force in the biotechnology industry, consistently ranking among the top-performing pharmaceutical companies and maintaining a robust pipeline of investigational therapies.

Explore more jobs of your matchFind more biopharma roles with GetBioJob.